For ophthalmic use only. Tilt head back, pull down the lower eyelid to form a pouch. Gently squeeze the dropper to instill one drop, then close the eye. Apply light pressure to the tear duct for one minute to minimize systemic absorption. If using other eye drops, wait at least 5 minutes between applications.

Brimonidine Tartrate is a relatively selective alpha-2 adrenergic agonist. It reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. The exact mechanism for increasing uveoscleral outflow is not fully elucidated but involves complex physiological pathways.

• •Hypersensitivity to Brimonidine Tartrate or any component of the formulation.
• •Patients receiving monoamine oxidase (MAO) inhibitors.
• •Neonates and infants (under 2 years of age).

Store at room temperature (below 30°C). Protect from light. Do not freeze. Keep out of reach of children.

Systemic overdose is unlikely due to minimal ocular absorption. However, symptoms of oral overdose in adults can include hypotension, bradycardia, drowsiness, and CNS depression. In children, severe CNS depression, bradycardia, apnea, and hypothermia have been reported. Treatment is supportive and symptomatic.

Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. It is unknown whether Brimonidine is excreted in human milk; caution should be exercised when administered to a nursing woman.